asymptomatic peripheral arterial disease and antioxidants in patients with diabetes and randomised placebo controlled trial of aspirin factorial disease and diabetes (POPADAD) trial: The prevention…

By S. Pringle, R. Macwalter, J. McKnight, C. Semple, J. Petrie, A. Jamieson, D. Matthews, A. Morris, R. Jung, C. Kelly and 9 more. 2008

832 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/599f09dc7263390a4832cbc2680bd514e8e2d447

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

V. Basevi
B. Bozkurt
R. Brindis
J. Regensteiner
M. D. Gerhard-Herman
M. Hlatky
L. Fleisher
H. Gornik

Citations in the corpus

Standards of Medical Care in Diabetes—2013 (2012, background): “Two recent RCTs of aspirin specifically in patients with diabetes failed to show a significant reduction in CVD end points, raising further questions about the efficacy of aspirin for primary prevention in people with diabetes (312,313).”
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly (2018, background): “Other race or ethnic group was defined as any category with less than 200 participants overall, which included Aboriginal or Torres Strait Islander (12 participants), Native American (6), multiple races or ethnic groups (64), Native Hawaiian or Pacific Islander (11), and those who indicated that the”
Standards of Medical Care in Diabetes—2012 (2011, background): “Two recent RCTs of aspirin specifically in patients with diabetes failed to show a significant reduction in CVD end points, raising further questions about the efficacy of aspirin for primary prevention in people with diabetes (272,273).”
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, methodology): “0 were randomized to daily aspirin or placebo.(139) In this study, there was no significant difference in the composite outcome of death from coronary heart disease or stroke, non-fatal myocardial infarction or stroke, or above ankle amputation for critical limb ischaemia; or any of its individual c”
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease (2016, background): “99), the usefulness of antiplatelet therapy to reduce the risk of MI, stroke, or vascular death is uncertain (75,76).”